0000950170-24-068730.txt : 20240604 0000950170-24-068730.hdr.sgml : 20240604 20240604163033 ACCESSION NUMBER: 0000950170-24-068730 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240531 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240604 DATE AS OF CHANGE: 20240604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kezar Life Sciences, Inc. CENTRAL INDEX KEY: 0001645666 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473366145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38542 FILM NUMBER: 241018614 BUSINESS ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-822-5600 MAIL ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 kzr-20240531.htm 8-K 8-K
0001645666false00016456662024-05-312024-05-31

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 31, 2024

 

 

Kezar Life Sciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38542

47-3366145

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4000 Shoreline Court, Suite 300

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 650 822-5600

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

KZR

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed on a Current Report on Form 8-K filed by Kezar Life Sciences, Inc. (the “Company”) on December 4, 2023, on December 1, 2023, the Company received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the previous 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until November May 29, 2024, to regain compliance with the minimum bid price requirement. As of the date of this Current Report on Form 8-K, the Company’s common stock has not regained compliance with the minimum bid price requirement.

 

However, the Company was notified by the Staff in a letter dated May 31, 2024 (the “Second Nasdaq Notice”), that the Company’s application to transfer to the Nasdaq Capital Market was approved and the Company is eligible for an additional 180 calendar day period, or until November 25, 2024 (the “Second Compliance Date”), to regain compliance with the minimum bid price requirement. At the opening of business on June 4, 2024, the Company’s common stock was transferred to the Nasdaq Capital Market, which operates in substantially the same manner as the Nasdaq Global Select Market, where it continues to trade under the symbol “KZR”.

 

The Company intends to actively monitor the closing bid price of its common stock between now and the Second Compliance Date and will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price rule, including by effecting a reverse stock split, if necessary.

 

If the Company does not regain compliance with the minimum bid price requirement by the Second Compliance Date, the Staff will notify the Company that its common stock will be subject to delisting. In the event of such a notification, the Company may appeal the Staff’s determination to delist its common stock before the Nasdaq Listing Qualifications Panel. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination, such an appeal would be successful.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

KEZAR LIFE SCIENCES, INC.

 

 

 

 

Date:

June 4, 2024

By:

/s/ Marc L. Belsky

 

 

 

Marc L. Belsky
Chief Financial Officer and Secretary

 

 EX-101.SCH 2 kzr-20240531.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
May 31, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 31, 2024
Entity Registrant Name Kezar Life Sciences, Inc.
Entity Central Index Key 0001645666
Entity Emerging Growth Company false
Entity File Number 001-38542
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-3366145
Entity Address, Address Line One 4000 Shoreline Court, Suite 300
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 822-5600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol KZR
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -"#Q%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #0@\18UM+$_.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R'%*&2;U9:6G#08K;.QF;+4UBV-C:R1]^R59FS*V!]C1TN]/ MGT"-B=*$A,\I1$SD,-\-ONVR-''#3D11 F1S0J]S.2:ZL7D(R6L:G^D(49L/ M?400G*_!(VFK2<,$+.)"9*JQ1IJ$FD*ZX*U9\/$SM3/,&L 6/7:4H2HK8&J: M&,]#V\ -,,$(D\_?!;0+<:[^B9T[P"[)(;LEU?=]V==S;MRA@K>GQY=YW<)U MF71G%W$_;!NH/[ MQ\970=7 K[M07U!+ P04 " #0@\18F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M -"#Q%@QGI4L7@0 *40 8 >&PO=V]R:W-H965T&UL MI9AO;ZLV%,:_BL6F:9/:\B>$IET2*4W;K>IM;U:Z7>E.>^& 2:P"YMHF:?;I M=TP2R#IRB+0W#0;.PX_CX^>8#M="OJDE8YJ\9VFN1M92Z^+:ME6T9!E5%Z)@ M.5Q)A,RHAJ%LYDDJLPR*C5:^Q,O?+'4YH0]'A9TP4*F?R]F$D9VK1+SC.6*BYQ(EHRLB7M]X_DF MH+KC#\[6ZN"8F%>9"_%F!@_QR'(,$4M9I(T$A9\5F[(T-4K \6TG:M7/-(&' MQWOU^^KEX67F5+&I2+_P6"]'UL B,4MHF>H7L?Z5[5ZH;_0BD:KJ+UEO[_5] MBT2ETB+;!0-!QO/M+WW?)>(@H.<="?!V 5[%O7U017E+-1T/I5@3:>X&-7-0 MO6H5#7 \-[,2:@E7.<3I\:V(2DBR)I,\)G>YYGI#'O+M;$/6AK:&AYA;[6@G M>+,5](X(/M$-Z;EGQ',\_]_1-J#5?%[-YU5RO2-R4[%BDOPYF2LM80;_:@/: M*OCM"J:LKU5!(S:RH&X5DRMFC7_XS@V'D*XQ02*&D*JC%[)X]LTT:)*SF.XP9^/P@"!&M08PU.P;K+F%SP?$%^@7B] M)%.1%31OA,/)?9G,DV%EP#\G3>&_1]#^%QG<9*G5.( MH!R$+(2L#/2,A!I6 !$2,E;"S,($B[BU\CK4;^\PR ._=T^!?*7OY"&&4N,) MCRI2)(D=DO[E>:\7!*[?QP@;QW=1P]X33N(8[!J6U^X 5EW.R.>\/7>XI \K M@H1+(9FY8F9":IB9DL/,]!P'PVX:@8M;^4?LJ1G!M+^*=7L;Q>5"V$(M24AS M<@]^%7$5"0RS:14N[O4?,>ORG$FQXF!HK:RXYG2"H37=P\5-_R/:3"@-1OB5 M%\?7#*YXY3L#=':;_N'BQE_-Y@3VO<=1<(&@CX(T3<+%O?V3B" GLZ7(,=OK M$!EXWGD_P N_Z0\N;NA?)->:Y:8C9&6^278>07K,AF&[6X0-&^QK/R=)^_QUZ'62->W MP[W[/V0/2I5 U@F(RW8"'NS_<>M^Y1H:O$B(Z_TX_XF$+"JAWEKW'1U*ICZA MS85:1&]GY'OG KH_*6 [MZ)IB<(V/<##3?M5TM@47;C)YJ*UY#H$'K^^8""- MRWNX(^_31.[>HR7-%^SH?K=#Z'D2WDY^:V.R#SXZS0?\$S7[0T52EH"28&N)X(H?<#\VE;_V=B_ ]02P,$% M @ T(/$6)^@&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK M0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZ MNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y M*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB6 M2;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9 M,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8 MDMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J* MW5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/ M[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*P MG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY M_U=3_ 102P,$% @ T(/$6)>*NQS $P( L !?3T\ M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5* M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'3 M6TGHX-R#8._AE8P=S8\?=_<#4$L#!!0 ( -"#Q%@D'INBK0 /@! : M >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E# M!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+ M[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " #0@\1899!YDAD! #/ M P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8; M8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 M E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D; M3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%- M)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'- MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 M ( -"#Q%@'04UB@0 +$ 0 " 0 !D;V-0&UL4$L! A0#% @ T(/$6-;2Q/SN *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ T(/$6)E< MG",0!@ G"< !, ( !S $ 'AL+W1H96UE+W1H96UE,2YX M;6Q02P$"% ,4 " #0@\18,9Z5+%X$ "E$ & @($- M" >&PO=V]R:W-H965T&UL4$L! A0#% @ T(/$6)^@ M&_"Q @ X@P T ( !H0P 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ T(/$6"0>FZ*M M ^ $ !H ( !TQ$ 'AL+U]R96QS+W=O9(9 0 SP, !, M ( !N!( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ A0 # end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports kzr-20240531.htm kzr-20240531.xsd http://xbrl.sec.gov/dei/2024 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "kzr-20240531.htm": { "nsprefix": "kzr", "nsuri": "http://www.kezarlifesciences.com/20240531", "dts": { "inline": { "local": [ "kzr-20240531.htm" ] }, "schema": { "local": [ "kzr-20240531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_27541c1b-e2b8-429c-a2fc-facebf6bb9c1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240531.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_27541c1b-e2b8-429c-a2fc-facebf6bb9c1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240531.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.kezarlifesciences.com/20240531/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 12 0000950170-24-068730-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-068730-xbrl.zip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kzr-20240531_htm.xml IDEA: XBRL DOCUMENT 0001645666 2024-05-31 2024-05-31 0001645666 false 8-K 2024-05-31 Kezar Life Sciences, Inc. DE 001-38542 47-3366145 4000 Shoreline Court, Suite 300 South San Francisco CA 94080 650 822-5600 false false false false Common Stock, $0.001 par value KZR NASDAQ false